secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001683168-24-005311
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals regains Nasdaq equity compliance after $9.9M share sale
---------------------------------------------------------------------------

- Shareholders' equity exceeds $5.0M, above Nasdaq's $2.5M minimum for continued listing.
- Sold 23,091,315 shares under A.G.P. agreement for gross proceeds of ~$9.9M.
- Cash on deposit $9.6M; company expects to fund operations through Q1 2025.
- Nasdaq Panel had granted final extension to Aug 12, 2024; delisting risk now resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005311/0001683168-24-005311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316824005311/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer